Objective—To determine the seroprevalences of and seroconversion rates for FeLV and FIV infection in cats treated for bite wounds and cutaneous abscesses and to evaluate compliance with recommendations to determine the retrovirus infection status of cats at acquisition and 60 days after a high-risk event.
Animals—967 cats from 134 veterinary practices in 30 states.
Procedures—Cats with bite wounds or abscesses were evaluated by use of a point-of-care immunoassay for blood-borne FeLV antigen and FIV antibody. Veterinarians were asked to retest cats approximately 60 days later to determine whether seronegative cats had seroconverted after injury.
Results—The combined FeLV-FIV status of only 96 (9.9%) cats was known prior to wound treatment. At the time of treatment, 187 (19.3%) cats were seropositive for 1 or both viruses. Age (adult), sex (male), history of cutaneous wounds, and outdoor access were significantly associated with seropositivity. At 73 of 134 (54.5%) veterinary practices, retesting of cats for retrovirus infection status was recommended to owners of 478 cats. Only 64 (13.4%) cats were retested; of these, 3 of 58 (5.2%) cats that were initially seronegative for FIV antibody seroconverted.
Conclusions and Clinical Relevance—A high proportion of cats with abscesses or bite wounds were seropositive for FeLV antigen or FIV antibody. Compliance with recommendations to test cats for retrovirus infection status at acquisition or after treatment for injury was low. The FeLV-FIV infection status of cats with potential fight wounds should be determined at time of treatment and again 60 days later.
Objective—To evaluate factors associated with survival in dogs with nasal carcinomas that did not receive treatment or received only palliative treatment.
Design—Retrospective case series.
Animals—139 dogs with histologically confirmed nasal carcinomas.
Procedures—Medical records, computed tomography images, and biopsy specimens of nasal carcinomas were reviewed. Only dogs that were not treated with radiation, surgery, chemotherapy, or immunotherapy and that survived ≥ 7 days from the date of diagnosis were included. The Kaplan-Meier method was used to estimate survival time. Factors potentially associated with survival were compared by use of log-rank and Wilcoxon rank sum tests. Multivariable survival analysis was performed by use of the Cox proportional hazards regression model.
Results—Overall median survival time was 95 days (95% confidence interval [CI], 73 to 113 days; range, 7 to 1,114 days). In dogs with epistaxis, the hazard of dying was 2.3 times that of dogs that did not have epistaxis. Median survival time of 107 dogs with epistaxis was 88 days (95% CI, 65 to 106 days) and that of 32 dogs without epistaxis was 224 days (95% CI, 54 to 467 days).
Conclusions and Clinical Relevance—The prognosis of dogs with untreated nasal carcinomas is poor. Treatment strategies to improve outcome should be pursued.